| Topic | Key Facts |
|---|---|
| What are GLP-1 medications | A class of prescription drugs that mimic gut hormones to reduce appetite and regulate blood sugar |
| FDA-approved for weight loss | Wegovy (semaglutide 2.4 mg), Zepbound (tirzepatide) |
| Who qualifies | BMI of 30 or higher, or BMI of 27 or higher with a weight-related condition |
| How telehealth delivery works | Virtual consultation, labs, ongoing monitoring, lifestyle support |
| Compounded semaglutide | Not FDA-approved; carries safety risks flagged by the FDA |
| When to see a doctor | Before starting any GLP-1 medication; a licensed clinician evaluates medical fit |
GLP-1 receptor agonists have changed the conversation around weight management in a meaningful way. These medications, once used primarily for type 2 diabetes, are now prescribed through a growing number of telehealth weight loss programs, and the clinical results are well-documented. The risks of obtaining them through platforms that skip proper medical evaluation are equally real.
This article covers what GLP-1 medications are, which ones are FDA-approved for obesity treatment, who is a legitimate candidate, and what a responsible telehealth weight loss program should look like. For anyone exploring this path, understanding the difference between structured medical care and a prescription shortcut matters.
What Are GLP-1 Medications and How Do They Work?
GLP-1 receptor agonists are a class of medications that mimic glucagon-like peptide-1, a hormone naturally released by the gut after eating. These drugs work by binding to GLP-1 receptors in the pancreas and brain, slowing gastric emptying, stimulating insulin release, and signaling a feeling of fullness. The result is reduced caloric intake over time, which, combined with lifestyle changes, produces clinically significant weight loss.
The newest GLP-1-based treatments produce weight loss averaging 15% to 21% in phase 3 clinical trials, along with improvements in cardiometabolic health, according to peer-reviewed trial data published in the New England Journal of Medicine.
These medications are not stimulants, appetite-suppressing pills in the traditional sense, or supplements. They are prescription drugs that require medical oversight for safe and appropriate use.
Which GLP-1 Medications Are FDA-Approved for Weight Loss?
Not all GLP-1 medications carry the same approval status. Understanding the difference between on-label and off-label use matters before starting any telehealth weight loss program.
Wegovy (Semaglutide 2.4 mg)
Wegovy is FDA-approved specifically for chronic weight management in adults with a BMI of 30 or higher, or a BMI of 27 or higher with at least one weight-related condition such as hypertension, type 2 diabetes, or high cholesterol. It is a once-weekly subcutaneous injection. Clinical trial data from the STEP 1 trial, published in the New England Journal of Medicine, showed an average body weight reduction of approximately 15% over 68 weeks.
Zepbound (Tirzepatide)
Zepbound is FDA-approved for chronic weight management and targets both GLP-1 and GIP (glucose-dependent insulinotropic polypeptide) receptors, making it a dual agonist. Phase 3 SURMOUNT-1 trial data, published in the New England Journal of Medicine, showed weight reductions of up to 21% at the highest dose. In a large real-world telehealth analysis of over 53,000 patients, tirzepatide was associated with an average 12-month weight loss of 21.2% among those who remained on the medication throughout the study period. Ard JD et al., Obesity, 2024
Ozempic (Semaglutide 1.0 mg or 2.0 mg), Off-Label for Weight Loss
Ozempic is FDA-approved for the treatment of type 2 diabetes, not for weight loss. Prescribing it specifically for obesity is considered off-label use. A prescribing physician may make this clinical decision for appropriate patients, but any telehealth platform offering it for weight loss should make this distinction transparent. Patients in the same real-world telehealth study who were on Ozempic at 12 months achieved an average weight loss of 13.8%. Ard JD et al., Obesity, 2024
Saxenda (Liraglutide 3.0 mg)
Saxenda is a once-daily injectable GLP-1 receptor agonist approved by the FDA for chronic weight management. It produces more modest results than newer agents. The SCALE trial, published in the New England Journal of Medicine, showed approximately 8% weight loss at 56 weeks. Real-world telehealth data found results of around 12% for patients who remained on this medication for 12 months. Ard JD et al., Obesity, 2024
Who Is a Legitimate Candidate for GLP-1 Treatment?
The FDA criteria for GLP-1 weight loss medications set a clinical threshold that a licensed provider must verify. Meeting these criteria does not automatically mean a prescription is appropriate, as a doctor considers the full clinical picture.
Standard FDA eligibility criteria for Wegovy and Zepbound:
- BMI of 30 kg/m² or higher (classified as obesity), or
- BMI of 27 to 29.9 kg/m² (overweight) with at least one weight-related comorbidity such as prediabetes, hypertension, type 2 diabetes, obstructive sleep apnea, or hyperlipidemia
Conditions that typically exclude someone from candidacy:
- Pregnancy or breastfeeding
- Personal or family history of medullary thyroid carcinoma (MTC)
- Multiple endocrine neoplasia syndrome type 2 (MEN 2)
- History of pancreatitis (in some cases)
- History of eating disorders such as anorexia or bulimia
In a real-world analysis of over 442,000 individuals who screened for a telehealth obesity program, approximately 29% were deemed medically ineligible based on criteria including BMI below 27, absence of a qualifying comorbidity, pregnancy, eating disorder history, or type 1 diabetes. Ard JD et al., Obesity, 2024 This reinforces that a medical evaluation is not a formality. A meaningful proportion of interested patients are appropriately directed away from these medications.
A telehealth endocrinologist or obesity medicine physician is best positioned to assess individual eligibility.
What a Proper Telehealth Evaluation Should Include
Receiving a GLP-1 prescription through a telehealth weight loss program is not, and should not be, as simple as answering a few questions online. A legitimate evaluation includes several distinct steps.
Full Medical History Review
A board-certified clinician should review current medications, past diagnoses, surgical history, kidney and liver function status, and any cardiovascular conditions. GLP-1 medications interact with other drugs and are contraindicated in specific conditions.
Baseline Lab Work
Lab testing before starting treatment supports clinical decision-making. Relevant tests typically include fasting blood glucose, HbA1c, a complete metabolic panel (including kidney and liver markers), lipid panel, and thyroid function. Some programs also assess thyroid-stimulating hormone given the thyroid-related contraindications associated with this medication class.
Cardiovascular Screening
Patients with pre-existing cardiovascular conditions require particular attention. The Endocrine Society's Clinical Practice Guideline on the Pharmacological Management of Obesity recommends that pharmacotherapy decisions be integrated with an assessment of cardiovascular risk.
Patient-Centered Discussion of Goals and Expectations
A qualified provider should discuss realistic outcomes, the timeline for weight loss, and the role of behavioral change alongside medication. GLP-1 medications are most effective when combined with nutritional guidance and physical activity, not as standalone interventions.
If a platform skips all of this and offers a prescription after a brief online form, that is a meaningful warning sign.
The Role of the Prescribing Doctor
Patients cannot self-select GLP-1 medications. A licensed physician, nurse practitioner, or physician assistant must determine medical appropriateness through a real clinical evaluation.
In structured telehealth programs, this typically means a virtual visit with a board-certified clinician who has training in obesity medicine or endocrinology. The Obesity Medicine Association's clinical practice guidelines describe a comprehensive patient evaluation as foundational to any treatment plan involving pharmacotherapy.
The prescribing doctor also makes ongoing clinical decisions, adjusting doses as needed, managing side effects, switching medications when a patient is not responding, and reconsidering treatment if it becomes medically inappropriate. This active clinical relationship is what separates a structured telehealth weight loss program from a platform focused only on dispensing prescriptions.
Working with a telehealth provider experienced in GLP-1 prescribing makes this ongoing management more accessible, particularly for patients without easy access to in-person obesity specialists.
What Ongoing Monitoring Looks Like
Starting a GLP-1 medication is a beginning, not a destination. Side effects, dose adjustments, and weight loss plateaus all require active management over time.
Side Effect Management
The most common side effects of GLP-1 medications are gastrointestinal: nausea, constipation, diarrhea, and heartburn. These tend to be most pronounced during the early weeks of treatment and at dose increases, and they typically decrease over time.
In a real-world telehealth study of 53,590 patients using antiobesity medications, nausea was the most frequently reported side effect, occurring in 29.2% of those who initiated treatment. Constipation was the second most common, reported by 18.5% of the same group. Side effect prevalence declined substantially over the treatment period, with nausea dropping below 10% for most medications by month 8. Ard JD et al., Obesity, 2024
A well-run telehealth program builds side effect monitoring into its check-in process as a clinically meaningful touchpoint, not a formality.
Dose Titration
GLP-1 medications are started at low doses and gradually increased, a process called titration, to minimize side effects and find an effective maintenance dose. This requires provider guidance at regular intervals. Monthly virtual check-ins with a clinician are standard practice in structured programs.
Nutrition and Lifestyle Support
The Obesity Medicine Association and the Endocrine Society both emphasize that pharmacotherapy for obesity should be accompanied by behavioral and nutritional support. A telehealth dietitian can play an important role in building sustainable habits alongside medication. Programs that include registered dietitians and fitness specialists as part of the care team show better long-term engagement.
The Real-World Evidence for Telehealth-Delivered GLP-1 Treatment
Telehealth delivery of GLP-1 obesity treatment has been studied at scale, not just in theory.
A retrospective analysis published in the journal Obesity in 2024 examined 12-month weight-loss outcomes in 53,590 patients who initiated antiobesity medication treatment through a large telehealth program. Researchers from Wake Forest University School of Medicine and the University of Florida analyzed real-world data from this cohort. Ard JD et al., Obesity, 2024
Key findings from this study:
- Average weight loss was 8.9% at 3 months, 14.1% at 6 months, 17.7% at 9 months, and 19.4% at 12 months
- GLP-1 receptor agonist-based medications were the most prescribed treatment category
- Side effects were consistent with those seen in phase 3 clinical trials and declined in frequency over time
- Program retention was 78% at 3 months and 77% at 12 months among eligible patients
- Tirzepatide (Mounjaro/Zepbound) was the most prescribed medication, associated with an average 21.2% weight loss at 12 months
The study authors concluded that these outcomes were comparable to those seen in phase 3 clinical trials, suggesting that a properly structured telehealth obesity treatment program can generalize beyond controlled research and in-person clinical settings.
"Telehealth-delivered treatment of obesity that includes current AOMs appears to produce comparable results with those seen in phase 3 clinical trials, suggesting that the results can be generalized beyond clinical trial and in-person settings." — Ard JD et al., Obesity, 2024
Compounded Semaglutide: What the FDA Has Said
During a period of semaglutide supply shortages, compounding pharmacies produced versions of semaglutide outside the standard FDA approval process. These compounded versions are not FDA-approved, have not been reviewed for safety, potency, or efficacy, and are not interchangeable with branded Wegovy or Ozempic.
The FDA has issued guidance noting that it received reports of adverse events associated with compounded semaglutide products. As of February 2025, the FDA resolved its determination of the semaglutide injection shortage, which affects how compounding pharmacies can legally produce these products under federal guidelines.
Patients considering compounded semaglutide should discuss this directly with a physician. A responsible telehealth program does not present compounded semaglutide as a routine equivalent to FDA-approved medications.
What to Look for When Evaluating a Telehealth Program
Not every platform offering GLP-1 prescriptions online operates with the same standard of care. The following are signs that a program may be moving too fast on prescribing and too light on oversight.
Prescriptions without a real clinical consultation. A short online form is not a medical evaluation. A licensed clinician must conduct an actual assessment before any prescription is appropriate.
No lab work required. Baseline labs are standard practice before prescribing GLP-1 medications. Skipping this step removes important safety information from the clinical picture.
No ongoing monitoring or follow-up structure. Monthly check-ins, side effect tracking, and dose management are part of proper care, not optional extras.
Compounded semaglutide presented as equivalent to Wegovy. These are not FDA-approved products. Any program presenting compounded semaglutide as a routine option without clinical discussion deserves a closer look.
Promises of rapid results without lifestyle guidance. GLP-1 medications produce meaningful results over months. Programs that focus on quick transformation without addressing nutrition and activity are overstating what pharmacotherapy alone can deliver.
No registered dietitian or behavioral support. Sustainable weight management requires more than a prescription. Programs without nutritional or behavioral resources provide incomplete care.
For help evaluating options and understanding what questions to ask, Momentary Lab's AI healthcare navigator can provide a useful starting point.
The Bottom Line: Medical Supervision Is the Point
GLP-1 medications represent a genuine clinical advancement for people managing obesity. The evidence supports their effectiveness when used appropriately, and telehealth has made access to qualified providers more realistic for more people.
The effectiveness of these treatments depends on proper patient selection, clinical oversight, side effect management, and lifestyle support. A prescription obtained through a platform that skips these steps is not a shortcut to better care. It removes the elements that make the care work.
Responsible programs take the time to evaluate whether a medication is appropriate, support patients through the adjustment period, and treat weight management as the ongoing medical condition it is.
If you are considering a telehealth weight loss program that includes GLP-1 medications, a doctor who specializes in obesity medicine or endocrinology is the right starting point.
Frequently Asked Questions
What is a telehealth weight loss program with GLP-1 medications? A telehealth weight loss program combines virtual medical consultations, prescription antiobesity medications (such as Wegovy or Zepbound), and ongoing clinical monitoring delivered entirely online. Patients meet with licensed providers through video visits, receive and manage prescriptions, and access support from dietitians and care coordinators without visiting a clinic in person.
Can I get Wegovy through a telehealth provider? Yes, a licensed telehealth clinician can evaluate eligibility and prescribe Wegovy if the patient meets FDA criteria: a BMI of 30 or higher, or a BMI of 27 or higher with a qualifying weight-related condition. The evaluation must include a medical history review and, in most responsible programs, baseline lab work.
Is semaglutide the same as Wegovy and Ozempic? Semaglutide is the active ingredient in both Wegovy and Ozempic, but the two products are not the same. Wegovy is dosed at 2.4 mg weekly and is FDA-approved for chronic weight management. Ozempic is FDA-approved for type 2 diabetes, and prescribing it for weight loss is considered off-label use.
What is the difference between tirzepatide and semaglutide for weight loss? Semaglutide (Wegovy) targets GLP-1 receptors. Tirzepatide (Zepbound) targets both GLP-1 and GIP receptors, making it a dual agonist. Phase 3 trial data suggest tirzepatide produces greater average weight loss at the highest doses. A prescribing physician determines which is appropriate based on individual medical history.
Is compounded semaglutide safe to use for weight loss? Compounded semaglutide is not FDA-approved, has not been evaluated for safety or efficacy through the standard regulatory review process, and is not interchangeable with branded Wegovy. The FDA has flagged safety concerns associated with compounded semaglutide products. Any discussion of compounded options should happen directly with a licensed physician.
What are the most common side effects of GLP-1 medications? The most common side effects are gastrointestinal, including nausea, constipation, diarrhea, and heartburn or indigestion. These are most common during the early weeks of treatment and at dose increases. In a large real-world study, nausea was reported by 29.2% of patients who initiated treatment, and side effect frequency declined notably over time. Ard JD et al., Obesity, 2024
Do telehealth weight loss programs actually work? Real-world data from a 12-month study of 53,590 patients in a structured telehealth program showed average weight loss of 19.4% at 12 months, consistent with phase 3 clinical trial results. Ard JD et al., Obesity, 2024 Results depend on the medication used, patient adherence, and the presence of lifestyle and behavioral support.
Can a telehealth endocrinologist or dietitian prescribe GLP-1 medications? A telehealth endocrinologist, obesity medicine physician, or other licensed prescriber can evaluate eligibility and prescribe GLP-1 medications through a virtual consultation. Registered dietitians cannot prescribe medications independently but are an important part of the care team for managing nutrition alongside medication.
How do I know if a telehealth weight loss platform is legitimate? Legitimate programs require a real clinical consultation with a licensed provider, conduct or require baseline lab work, include ongoing monthly monitoring, are transparent about which medications are FDA-approved versus off-label, and provide access to dietary or behavioral support. Platforms that offer prescriptions based on a short online form without clinical review warrant caution.
What happens if I stop taking a GLP-1 medication? Stopping a GLP-1 medication typically results in some degree of weight regain over time, as the appetite-regulating effects of the medication are no longer present. This is a recognized characteristic of pharmacotherapy for obesity and not a sign that treatment failed. A physician can advise on maintenance strategies and whether long-term treatment is appropriate for individual cases.
